PMID- 30542467
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 1792-0981 (Print)
IS  - 1792-1015 (Electronic)
IS  - 1792-0981 (Linking)
VI  - 16
IP  - 6
DP  - 2018 Dec
TI  - Dendritic cell vaccine with Ag85A enhances anti-colorectal carcinoma immunity.
PG  - 5123-5129
LID - 10.3892/etm.2018.6851 [doi]
AB  - Dendritic cells (DCs) are able to trigger T-cell activation and thus have been 
      considered important for vaccine production against cancers. Vaccines containing 
      DCs have been reported to be effective for developing immunity against cancer 
      cells. The interactions between DCs and auxiliary agents are critical in the 
      development of second-generation vaccines. In the present study, it was evaluated 
      whether Ag85A-mixed DCs could enhance anti-tumor immunity in laboratory mice with 
      colorectal carcinoma. Functional and phenotypic analyses of the effects of 
      Ag85A-mixed DCs were conducted via flow cytometry and measurement of T-cell 
      proliferation. In addition, interferon (IFN)-gamma production was assessed. The 
      therapeutic efficacy of DC vaccination for colorectal carcinoma treatment in mice 
      was investigated. It was identified that Ag85A-mixed DCs exhibited strong 
      upregulation of CD80, CD86 and major histocompatibility complex class II. 
      Cytotoxic T-lymphocytes with CT26-primed Ag85A-DCs were indicated to induce 
      stronger responses against CT26 tumor cells and trigger IFN-gamma production. 
      Furthermore, the Ag85A-mixed DC vaccine exerted a considerable inhibitory effect 
      on tumor progression in mice as compared with the control group. Therefore, DCs 
      in combination with the Ag85A gene may reinforce anti-colorectal carcinoma 
      immunity. The current study provides a novel potential strategy for cancer 
      treatment by enhancing immunity via Ag85A-mixed DC vaccination.
FAU - Zhai, Jingbo
AU  - Zhai J
AD  - Brucellosis Institute of Inner Mongolia University for The Nationalities, 
      Tongliao, Inner Mongolia 028000, P.R. China.
AD  - Department of Immunology, China Medical University, Shenyang, Liaoning 110122, 
      P.R. China.
AD  - Brucellosis Prevention and Treatment Engineering Technology Research Center of 
      Inner Mongolia Autonomous Region, Tongliao, Inner Mongolia 028042, P.R. China.
FAU - Gao, Wei
AU  - Gao W
AD  - Brucellosis Institute of Inner Mongolia University for The Nationalities, 
      Tongliao, Inner Mongolia 028000, P.R. China.
AD  - Brucellosis Prevention and Treatment Engineering Technology Research Center of 
      Inner Mongolia Autonomous Region, Tongliao, Inner Mongolia 028042, P.R. China.
FAU - Zhao, Leheng
AU  - Zhao L
AD  - Brucellosis Institute of Inner Mongolia University for The Nationalities, 
      Tongliao, Inner Mongolia 028000, P.R. China.
AD  - Brucellosis Prevention and Treatment Engineering Technology Research Center of 
      Inner Mongolia Autonomous Region, Tongliao, Inner Mongolia 028042, P.R. China.
FAU - Gao, Zhipeng
AU  - Gao Z
AD  - Department of Urology, The First Hospital of China Medical University, Shenyang, 
      Liaoning 110001, P.R. China.
FAU - Jiang, Xuefeng
AU  - Jiang X
AD  - Department of Immunology, China Medical University, Shenyang, Liaoning 110122, 
      P.R. China.
FAU - Lu, Changlong
AU  - Lu C
AD  - Brucellosis Institute of Inner Mongolia University for The Nationalities, 
      Tongliao, Inner Mongolia 028000, P.R. China.
AD  - Department of Immunology, China Medical University, Shenyang, Liaoning 110122, 
      P.R. China.
AD  - Brucellosis Prevention and Treatment Engineering Technology Research Center of 
      Inner Mongolia Autonomous Region, Tongliao, Inner Mongolia 028042, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20181011
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC6257656
OTO - NOTNLM
OT  - antigen 85A
OT  - colorectal carcinoma
OT  - dendritic cells
OT  - major histocompatibility complex class II
EDAT- 2018/12/14 06:00
MHDA- 2018/12/14 06:01
PMCR- 2018/10/11
CRDT- 2018/12/14 06:00
PHST- 2018/04/24 00:00 [received]
PHST- 2018/08/31 00:00 [accepted]
PHST- 2018/12/14 06:00 [entrez]
PHST- 2018/12/14 06:00 [pubmed]
PHST- 2018/12/14 06:01 [medline]
PHST- 2018/10/11 00:00 [pmc-release]
AID - ETM-0-0-6851 [pii]
AID - 10.3892/etm.2018.6851 [doi]
PST - ppublish
SO  - Exp Ther Med. 2018 Dec;16(6):5123-5129. doi: 10.3892/etm.2018.6851. Epub 2018 Oct 
      11.